Journals / Abant Tıp Dergisi / 2015 / Cilt: 4 - Sayı: 4

Effect of neoadjuvant chemoradiation on local control and disease-free survival in locally advanced rectal neoplasms

Lokal İleri Evre Rektum Tümörlerinde Neoadjuvan Kemoradyoterapinin Lokal Kontrol ve Hastalıksız Sağkalım Üzerine Etkisi

Pages
338–350
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, further studies are required to understand the long-term follow-up results of recurrence and survival/disease-free survival in patients with locally advanced rectal cancer who received long-term neoadjuvant CRT.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Although surgery comprises the basis for the treatment of locally advanced rectal cancer, the feasibility of curative resection and sphincter-sparing surgery depending on the reduction in tumour size has been reported to increase with neoadjuvant chemoradiation CRT in patients with locally advanced rectal cancer.
📊
Key Findings & Data:The aim of this study was to investigate recurrence, survival with disease/disease-free survival and factors affecting them in patients who underwent surgery after receiving neoadjuvant CRT.METHODS: The files of 79 patients aged older than 18 years who were diagnosed with locally advanced rectal cancer and underwent surgery after receiving neoadjuvant CRT between January 2007 and May 2012 were retrospectively analysed in terms of demographics and clinical, radiological and pathological data.RESULTS: : A total of 79 patients, among whom 27 34.2% were females and 52 65.8% were males, were included in the study, and the mean age was 60.82±5 years.
💡
Conclusion & Impact:Thus, further studies are required to understand the long-term follow-up results of recurrence and survival/disease-free survival in patients with locally advanced rectal cancer who received long-term neoadjuvant CRT.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Lokal ileri rektum kanseri · neadjuan kemoradyoterapi · hastalıksiz sağkalım

Abstract

OBJECTIVE: Although surgery comprises the basis for the treatment of locally advanced rectal cancer, the feasibility of curative resection and sphincter-sparing surgery depending on the reduction in tumour size has been reported to increase with neoadjuvant chemoradiation CRT in patients with locally advanced rectal cancer. The aim of this study was to investigate recurrence, survival with disease/disease-free survival and factors affecting them in patients who underwent surgery after receiving neoadjuvant CRT.METHODS: The files of 79 patients aged older than 18 years who were diagnosed with locally advanced rectal cancer and underwent surgery after receiving neoadjuvant CRT between January 2007 and May 2012 were retrospectively analysed in terms of demographics and clinical, radiological and pathological data.RESULTS: : A total of 79 patients, among whom 27 34.2% were females and 52 65.8% were males, were included in the study, and the mean age was 60.82±5 years. The complete regression rate after neoadjuvant CRT was 15.18%. The average follow-up period of the patients was 26 months range: 3–59 months . During the follow up, tumour recurrence was detected in 28 35.44% patients, among whom 12 had local recurrence and 17 had systemic recurrence; the survival rate of the patients was 83.54%. The disease-free survival rate was 72.15%. In most of the patients, stage regression and the reduction of tumour size were achieved.CONCLUSION: In summary, hyperfractionated radiotherapy sterilises the margins of the mesorectum and prevents the development of tumour cell remnants, thus reducing the likelihood of local recurrence and preventing tumour cells from metastasising to remote organs. The ideal surgical technique after neoadjuvant CRT is total mesorectal excision. The important question is the optimum time for surgery after CRT. Thus, further studies are required to understand the long-term follow-up results of recurrence and survival/disease-free survival in patients with locally advanced rectal cancer who received long-term neoadjuvant CRT.

Özet

AMAÇ: Lokal ileri rektum kanserlerinde tedavinin temelini cerrahi oluştuşturmakla beraber neoadjuvan kemoradyoterapi KRT ile lokal ileri rektum kanserlerinde tümör boyutunda küçülmeye bağlı küratif rezeksiyon ve sfinkter koruyucu cerrahi yapılabilirliğinin arttığı bildirilmiştir. Bu çalışmanın amacı, neoadjuvan KRT aldıktan sonra cerrahi tedavi yapılan hastalarda rekürrens, hastalıksız /hastalıklı sağkalım ve buna etki eden faktörlerin araştırılmasıdır.YÖNTEMLER: Ocak 2007- Mayıs 2012 tarihleri arasında lokal ileri rektum kanseri tanısı konularak neoadjuvan KRT sonrası ameliyat edilmiş olan 18 yaş üstü 79 hastanın dosya kayıtları; demografik, klinik, radyolojik ve patolojik veriler açısından retrospektif olarak incelendi.BULGULAR: Çalışmaya 27 %34.2 kadın, 52 %65,8 erkek olmak üzere toplam 79 hasta katılmış olup ortalama yaş 60,82±5’ dir. Neoadjuvan KRT sonrası tam regresyon oranı %15,18’dir. Hastaların ortalama takip süresi, 26 ay 3-59 ay aralığında olarak saptandı. Takip süresince 28 %35,44 hastada tümör rekürrensi saptanmış olup bunun 12 tanesi lokal, 17 tanesi sistemik rekürrensti. Takip süresince hastaların hayatta kalımı %.83,54 idi. Hastalıksız sağ kalım ise %.72,15 idi. Hastaların büyük çoğunluğunda evre gerilemesi ve tümör boyutlarında küçülme sağlandı.SONUÇ: Hiperfraksiyone RT mezorektumun sınırlarını sterilize eder ve tümör hücre kalıntılarının gelişmesini engeller. Bu durum lokal nüks ihtimalini azaltır ve muhtemelen tümör hücrelerinin uzak organlara giderek metastaz yapmasını da engellemiş olur. Neoadjuvan KRT sonrası yapılacak ideal ameliyat tekniği Total mezorektal eksizyon‘ dur. Cevaplanması gereken önemli soru ise KRT sonrası ideal ameliyat zamanlamasının ne olduğudurÇalışmamızda olgu sayısının az olması ve takip süresinin kısa olması nedeni ile uzun dönem neoadjuvan kemoradyoterapi uygulanan lokal ileri rektum kanserli hastalarda nüks, sağkalım/ hastalıksız sağkalımın uzun dönem takip sonuçlarının anlaşılması için başka çalışmalara ihtiyaç vardır.

🔖

Cite This Article

BAYHAN, Z., KURT, R., UZUNOĞLU, H., ÖZBAY, O., TİRYAKİ, Ç., KARĞI, E. (2022). Effect of neoadjuvant chemoradiation on local control and disease-free survival in locally advanced rectal neoplasms. Abant Tıp Dergisi, Cilt: 4 - Sayı: 4, 338–350. https://ajindex.com/articles/427098

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007 Mar;18(3):581-592.
  2. Kulu Y, Muller-Stich BP, Bruckner T, Gehrig T, Buchler MW, Bergmann F, et al. Radical Surgery with Total Mesorectal Excision in Patients with T1 Rectal Cancer. Ann Surg Oncol. 2014 Oct 21. Shaikh I, Aston W, Hellawell G, Ross D, Littler S, Burling D, et al. Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall. Tech Coloproctol. 2014 Nov 8. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005 May;241(5):829-836; discussion 836-828.
  3. Altini C, Niccoli Asabella A, De Luca R, Fanelli M, Caliandro C, Quartuccio N, et al. Comparison of F- FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer. Abdom Imaging. 2014 Oct 28. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, et al. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. 15;119(24):4231-4241.
  4. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12(1):19-23.
  5. Ballinger AB, Anggiansah C. Colorectal cancer. Bmj. 2007 Oct 6;335(7622):715-718.
  6. Kehoe J, Khatri VP. Staging and prognosis of colon cancer. Surg Oncol Clin N Am. 2006 Jan;15(1):129-146.
  7. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007 May 1;109(9):1750-1755.
  8. Eche N, Pichon MF, Quillien V, Gory-Delabaere G, Riedinger JM, Basuyau JP, et al. [Standards, options and recommendations for tumor markers in colorectal Dec;88(12):1177-1206.
  9. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, et al. Tumor downstaging and sphincter chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027- 1038. Willett CG, Warland G, Coen J, Shellit